Joseph M. Palumbo, MD, LFAPA, MACPsych, is Executive Vice President (EVP), Head of Research & Development (R&D) and Chief Medical Officer (CMO) of BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Palumbo is a seasoned pre-clinical and translational researcher who’s equally equipped to bring drugs to market through his experience playing key roles in several successful global registrational programs at industry-leading pharmaceutical companies. In his current role at BioVie, Palumbo oversees the Company’s clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of neuroinflammation and insulin resistance, and BIV201 (continuous infusion terlipressin), an active agent used in over 40 countries to treat complications of liver cirrhosis. In addition to his role at BioVie, Palumbo is a Life Fellow of the American Psychiatric Association (APA) and a Fellow of the American Society for Clinical Pharmacology (for which he was also previously a member of the Steering Committee). He is also involved in academia, serving as a member of the American College of Psychiatrists along with sitting on the Dean’s Council of Advisors at The George Washington University School of Medicine and Health Sciences.

Palumbo joined BioVie from Zynerba (a company developing therapeutics for autism and other rare neuropsychiatric and neurodevelopmental conditions of adults and children), where he served as CMO leading clinical operations, development, regulatory and medical affairs. He previously held senior worldwide governance roles at Mitsubishi Tanabe Pharma in both the United States (US) and Japan, where he led medical science and translational research across multiple therapeutic areas, and guided successful registrational programs for RADICAVA® (edaravone) for the treatment of amyotrophic lateral sclerosis in the US, Canada, Japan, Switzerland, South Korea, and other countries. Palumbo also served as Global Head and Franchise Medical Leader for Psychiatry, and the Interim Head of Global Neuroscience at Johnson & Johnson, where he led the medical teams who achieved successful global registrations in multiple neurological conditions for RISPERDAL® (risperidone), CONCERTA® (methylphenidate HCL) and INVEGA® (paliperidone). He has also served on the executive teams of international pharmaceutical companies including Sanofi-Synthelabo and Cephalon, as well as senior leadership roles at prestigious academic institutions including Yale University, Cornell University and the University of Pennsylvania.

Dr. Palumbo holds a BA from the University of Pennsylvania and a Doctor of Medicine from the George Washington University School of Medicine. He was a Biological Sciences Training Program Fellow of the National Institutes of Health, a research mentor of junior faculty at both the APA and the Society of Biological Psychiatry, and served as Chief Resident for the Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University. Dr Palumbo has also received Board Certification in Psychiatry and Addiction Psychiatry.